Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 20,000 Shares

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00. Following the sale, the chief financial officer owned 110,180 shares in the company, valued at $1,211,980. This trade represents a 15.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Down 2.6%

Shares of DRTS stock opened at $10.88 on Friday. Alpha Tau Medical Ltd. has a 12-month low of $2.87 and a 12-month high of $11.62. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average of $9.39 and a 200-day moving average of $7.61. The company has a market capitalization of $982.79 million, a price-to-earnings ratio of -16.24 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). As a group, equities research analysts predict that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently modified their holdings of DRTS. Apella Capital LLC bought a new position in Alpha Tau Medical during the fourth quarter worth about $1,892,000. Daytona Street Capital LLC acquired a new position in Alpha Tau Medical during the fourth quarter worth approximately $749,000. Mariner LLC raised its stake in Alpha Tau Medical by 185.8% in the third quarter. Mariner LLC now owns 123,250 shares of the company’s stock valued at $556,000 after buying an additional 80,129 shares during the period. Millennium Management LLC lifted its position in shares of Alpha Tau Medical by 185.7% in the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after buying an additional 70,081 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Alpha Tau Medical in the first quarter valued at approximately $286,000. 2.65% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DRTS shares. LADENBURG THALM/SH SH boosted their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Barclays increased their price objective on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Finally, Citigroup lifted their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Alpha Tau Medical has a consensus rating of “Hold” and an average price target of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.